Phaseline

Targets › B4GALNT1

B4GALNT1 (Beta-1,4 N-acetylgalactosaminyltransferase 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.

Involved in the biosynthesis of gangliosides GM2, GD2, GT2 and GA2 from GM3, GD3, GT3 and GA3, respectively. (UniProt, Q00973)

Open in Phaseline: the race on B4GALNT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Prof. Dr. Dr. Birgit BurkhardtDinutuximab beta
Anti-GD2 monoclonal antibody
B4GALNT1Phase 1High-risk GD2 Positive Ewing SarkomaMar 2027
University Hospital Southampton NHS Foundation TrustCh14.18/CHO
Anti-GD2 monoclonal antibody
B4GALNT1Phase 1Neuroblastoma–

Conditions

Neuroblastoma (1) High-risk GD2 Positive Ewing Sarkoma (1)

Modalities

antibody (2)

Companies

University Hospital Southampton NHS Foundation Trust (1) Prof. Dr. Dr. Birgit Burkhardt (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.